Colleen Annesley

3.1k total citations · 1 hit paper
52 papers, 1.8k citations indexed

About

Colleen Annesley is a scholar working on Oncology, Hematology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Colleen Annesley has authored 52 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 15 papers in Hematology and 12 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Colleen Annesley's work include CAR-T cell therapy research (40 papers), Acute Lymphoblastic Leukemia research (12 papers) and Acute Myeloid Leukemia Research (11 papers). Colleen Annesley is often cited by papers focused on CAR-T cell therapy research (40 papers), Acute Lymphoblastic Leukemia research (12 papers) and Acute Myeloid Leukemia Research (11 papers). Colleen Annesley collaborates with scholars based in United States, Switzerland and Canada. Colleen Annesley's co-authors include Corinne Summers, Julie R. Park, Michael C. Jensen, Olivia Finney, Kasey J. Leger, Stephanie Mgebroff, Catherine Lindgren, Patrick A. Brown, Hannah Brakke and Rebecca Gardner and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Colleen Annesley

50 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

2017 787 citations Rebecca Gardner, Olivia Finney et al. Blood profile →

Peers

Countries citing papers authored by Colleen Annesley

Since Specialization

Citations

This map shows the geographic impact of Colleen Annesley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Colleen Annesley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Colleen Annesley more than expected).

Fields of papers citing papers by Colleen Annesley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Colleen Annesley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Colleen Annesley. The network helps show where Colleen Annesley may publish in the future.

Co-authorship network of co-authors of Colleen Annesley

This figure shows the co-authorship network connecting the top 25 collaborators of Colleen Annesley. A scholar is included among the top collaborators of Colleen Annesley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Colleen Annesley. Colleen Annesley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Outcomes of PLAT-02 and PLAT-03: Evaluating CD19 CAR T-Cell Therapy and CD19-expressing T-APC Support in Pediatric B-ALL 2025 ·Blood ·Colleen Annesley, Kristy Seidel, Qian Wu, Corinne Summers, Alan S. Wayne, Michael A. Pulsipher, Anurag K. Agrawal, Christopher T. Brown, Stephanie Mgebroff, Catherine Lindgren, Stephanie Rawlings-Rhea, Wenjun Huang, (unknown), Michael C. Jensen, Julie R. Park, Rebecca Gardner	2
2	Management Practices of CAR T-cell-Related Inflammatory Toxicities: A Survey of Pediatric CAR T-cell Providers 2025 ·Transplantation and Cellular Therapy ·Kevin O. McNerney, Caroline Diorio, Colleen Annesley, Rebecca Gardner, Andrea K. Graham, L. Nelson Sanchez‐Pinto, Amanda K. Ombrello, Aimee C. Talleur, (unknown), Liora M. Schultz, Shannon L. Maude, Nirali N. Shah	1
3	Low Peripheral Blood Counts and Elevated Proinflammatory Cytokines Signal a Poor CD19 Chimeric Antigen Receptor T-cell Response in Acute Lymphoblastic Leukemia 2025 ·Transplantation and Cellular Therapy ·(unknown), Kelly G. Stratton, Jenny L. Smith, Michael C. Jensen, Cameron J. Turtle, Camille Keenan, Colleen Annesley, Corinne Summers, Bobbie‐Jo Webb‐Robertson, Alexandre V. Hirayama, Rebecca Gardner, (unknown)	1
4	Clinical Factors Associated with Prolonged Cytopenias in Children and Young Adults Treated with CD19-Directed CAR T Cells (CAR19) for Acute Lymphoblastic Leukemia 2025 ·Transplantation and Cellular Therapy ·Regina M. Myers, Yimei Li, Adam J. Lamble, Emily M. Hsieh, Samuel John, J. Gregory Dolan, Hongyan Liu, Lee Chen, (unknown), Amanda M. DiNofia, Colleen Annesley, Stephan A. Grupp, (unknown), Rebecca Gardner, Lia Gore, Susan R. Rheingold, Nirali N. Shah, Michael A. Pulsipher	0
5	Tumor inflammation-associated neurotoxicity in children with diffuse intrinsic pontine glioma receiving B7-H3-targeting CAR T cells on BrainChild-03 2025 ·Neuro-Oncology Practice ·Rebecca Ronsley, Michelle Choe, Jason N. Wright, Kristy Seidel, (unknown), Jason Wendler, Colleen Annesley, Michael C. Jensen, Julie R. Park, Nicholas A. Vitanza, (unknown)	1
6	Feasibility and favorable responses after investigational CAR T-cell therapy for relapsed and refractory infant ALL 2024 ·Blood Advances ·Colleen Annesley, Adam J. Lamble, Corinne Summers, Michael A. Pulsipher, Alan S. Wayne, Julie Rivers, Wenjun Huang, (unknown), Qian Wu, Kristy Seidel, Stephanie Mgebroff, Christopher T. Brown, Catherine Lindgren, Julie R. Park, Michael C. Jensen, Rebecca Gardner	2
7	Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia 2024 ·Blood ·(unknown), Sara Silbert, Kai Rejeski, Keith Wilson, Adam J. Lamble, Yannis K. Valtis, Bonnie Yates, (unknown), Roni Shouval, (unknown), Rebecca Gardner, Haneen Shalabi, Colleen Annesley, Jae H. Park, (unknown), Nirali N. Shah	5
8	Plasticity of lineage switch in B-ALL allows for successful rechallenge with CD19-directed immunotherapy 2023 ·Blood Advances ·(unknown), Corinne Summers, Karen M. Chisholm, Sandra D. Bohling, Kasey J. Leger, Rebecca Gardner, Colleen Annesley, Adam J. Lamble	4
9	Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure 2023 ·Transplantation and Cellular Therapy ·(unknown), Bonnie Yates, Seth M. Steinberg, Constance M. Yuan, Hao‐Wei Wang, Colleen Annesley, Haneen Shalabi, David F. Stroncek, Terry J. Fry, Joerg Krueger, Elad Jacoby, Emily M. Hsieh, Deepa Bhojwani, Rebecca Gardner, Shannon L. Maude, Nirali N. Shah	4
10	Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia 2023 ·Molecular Therapy ·Santhosh Kumar Pasupuleti, (unknown), (unknown), (unknown), Lakshmi Reddy Palam, Sheng Liu, Jun Wan, Colleen Annesley, Mignon L. Loh, Elliot Stieglitz, Michael J. Burke, Reuben Kapur	4
11	GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients 2022 ·Blood Advances ·Juliane Gust, Stephanie Rawlings-Rhea, Ashley Wilson, (unknown), (unknown), Kristy Seidel, Qian Wu, Julie R. Park, Rebecca Gardner, Colleen Annesley	18
12	Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult Subjects 2022 ·Cancer Immunology Research ·Francesco Ceppi, Ashley Wilson, Colleen Annesley, (unknown), Corinne Summers, Adam Brand, Kristy Seidel, Qian Wu, (unknown), Christopher Brown, Stephanie Mgebroff, Catherine Lindgren, Stephanie Rawlings-Rhea, Wenjun Huang, Michael A. Pulsipher, Alan S. Wayne, Julie R. Park, Michael C. Jensen, Rebecca Gardner	14
13	CD22 CAR Optimization for Improved in-Human Activity Following Inadequate CD22 CAR Activity in Phase 1 Clinical Trial PLAT-04 2021 ·Blood ·Corinne Summers, (unknown), Colleen Annesley, Jason K. Yokoyama, (unknown), Wenjun Huang, Ashley Wilson, Julie R. Park, Rimas J. Orentas, Michael C. Jensen, Rebecca Gardner	4
14	Hematopoietic Cell Transplantation after CD19 Chimeric Antigen Receptor T Cell-Induced Acute Lymphoblastic Leukemia Remission Confers a Leukemia-Free Survival Advantage 2021 ·Transplantation and Cellular Therapy ·Corinne Summers, Qian Wu, Colleen Annesley, Marie Bleakley, Ann Dahlberg, (unknown), Wenjun Huang, Jenna Voutsinas, Adam Brand, Wendy M. Leisenring, Michael C. Jensen, Julie R. Park, Rebecca Gardner	44
15	SCRI-CAR19x22v2 T Cell Product Demonstrates Bispecific Activity in B-ALL 2021 ·Blood ·Colleen Annesley, Corinne Summers, Michael A. Pulsipher, Jodi Skiles, Amanda M. Li, Anant Vatsayan, Catherine Lindgren, Stephanie Mgebroff, Ashley Wilson, Wenjun Huang, Qian Wu, Joshua D. Gustafson, (unknown), Michael C. Jensen, Julie R. Park, Rebecca Gardner	16
16	A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study 2016 ·Clinical Cancer Research ·Todd M. Cooper, (unknown), Elena Eckroth, Jemily Malvar, Richard Sposto, Paul S. Gaynon, Bill H. Chang, Lia Gore, Keith J. August, Jessica A. Pollard, Steven G. DuBois, Lewis B. Silverman, Javier Oesterheld, Guy Gammon, Daniel Magoon, Colleen Annesley, Patrick A. Brown	56
17	CD19CAR T Cell Products of Defined CD4:CD8 Composition and Transgene Expression Show Prolonged Persistence and Durable MRD-Negative Remission in Pediatric and Young Adult B-Cell ALL 2016 ·Blood ·Rebecca Gardner, Olivia Finney, Hannah Smithers, Kasey J. Leger, Colleen Annesley, Corinne Summers, Christopher Brown, Stephanie Mgebroff, Catherine Lindgren, (unknown), Assaf P. Oron, D. Li, Marie Bleakley, Julie R. Park, Michael C. Jensen	31
18	POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL 2015 ·Oncotarget ·Edward Allan R. Sison, Daniel Magoon, Li Li, Colleen Annesley, Bárbara Romagnoli, Garry J. Douglas, Gérald Tuffin, Johann Zimmermann, Patrick A. Brown	29
19	Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition 2014 ·Oncotarget ·Edward Allan R. Sison, Daniel Magoon, Li Li, Colleen Annesley, Rachel E. Rau, Donald Small, Patrick A. Brown	49
20	The Biology and Targeting of FLT3 in Pediatric Leukemia 2014 ·Frontiers in Oncology ·Colleen Annesley, Patrick A. Brown	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact